EANS-Adhoc: SYGNIS Pharma AG SYGNIS Pharma AG successfully completes capital
increase
--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
10.08.2011
Ad-hoc release
SYGNIS Pharma AG successfully completes capital increase
Heidelberg, 10 August 2011 - The shareholders of SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) exercised their subscription and over-
subscription rights for 3,076,623 new no-par value bearer shares at a
subscription price of euro 2.00 per new share by the end of the subscription
period on 9 August 2011.
SYGNIS plans to use the gross proceeds of approximately euro 6.15 million from
this capital increase to finance in particular the completion and the potential
commercialization of its current efficacy trial of AX200 for the treatment of
acute stroke (AXIS 2) as well as the development of its preclinical KIBRA-
project.
SYGNIS' main shareholder - dievini Hopp BioTech holding GmbH & Co. KG,
Walldorf, Germany - has exercised its subscription and over-subscription rights
for a total of 3 million new shares at the subscription price. In receipt of
these new shares dievini has invested funds equal to the loan-amount dievini
has committed in June 2011. According to the contractual terms of the loan
agreement such commitment ceases to apply automatically with this equity
investment. As a result, dievini will hold approximately 54,5% of shares
outstanding in SYGNIS.
Following the entry of the capital increase in the Commercial Register - which
is scheduled for 15 August 2011 - the total number of SYGNIS shares issued will
increase to 16,829,504. Accordingly the equity capital will increase from euro
13,752,881 to euro 16,829,504. The subscribed and allocated new SYGNIS shares
are expected to be delivered, after they have been listed on the stock
exchange, and to begin trading on the stock exchange on 17 August 2011. The
capital increase is being conducted by Landesbank Baden-Württemberg, Stuttgart,
Germany.
For further information please contact:
|Dr. Franz-Werner Haas |
|Senior VP Operations |
|Tel: +49 (0) 6221-454 812 |
|Email: franz-Werner.haas@sygnis.de |
### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. The shares in SYGNIS Pharma
AG (the 'Shares') may not be offered or sold in the United States or to or for
the account or benefit of 'U.S. persons' (as such term is defined in Regulation
S under the U.S. Securities Act of 1933, as amended (the 'Securities Act')). No
offer or sale of transferable securities is being made to the public. The
shares are offered solely on the basis of subscription rights.
This document is only being distributed to and is only directed at (i) persons
who are outside the United Kingdom or (ii) to investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the 'Order') or (iii) high net worth entities, and other
persons to whom it may lawfully be communicated, falling within Article
49(2)(a) to (d) of the Order (all such persons together being referred to as
'relevant persons'). The Shares are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such securities
will be engaged in only with, relevant persons. Any person who is not a
relevant person should not act or rely on this document or any of its contents.
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered to
be total guarantees since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS Pharma AG
may deviate greatly from the established conclusions or implied predictions
contained in such statements. SYGNIS does not undertake to publicly update or
revise these statements in the light of new information or future results or
for any other reason.
###
Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English